Form 8-K · Current Report · Filed 2026-04-29
Regeneron Reports Strong Q1 2026 Financial Results and Authorizes New Share Repurchase Program
Regeneron Pharmaceuticals, Inc. reported strong financial results for the first quarter of 2026, with total revenues increasing by 19% to $3.6 billion. The company saw significant growth in net product sales, particularly for Dupixent and EYLEA HD. Regeneron also authorized a new $3.0 billion share repurchase program. Key pipeline updates include FDA approvals for Dupixent and EYLEA HD, and the approval of Otarmeni, the first gene therapy for genetic hearing loss. The company's board also declared a cash dividend of $0.94 per share, payable on June 4, 2026.
- Filer
- Regeneron Pharmaceuticals, Inc. REGN · NASDAQ
- Filed
- Accession
- 0000872589-26-000014
- CIK
- 0000872589
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$731.77
Next session
-3.4%
Since filing
+4.2%
Latest close
$762.63
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from REGN reporting the same item, with the next session's move:
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of medicines for serious medical conditions. The company's primary function is to address unmet medical needs through innovative treatments derived from its robust pipeline of pharmaceutical products. Regeneron is particularly notable for its contributions to the healthcare industry with products that target ailments such as eye diseases, inflammatory conditions, and cancer. Among its key offerings are EYLEA, an injection for retinal diseases, and Dupixent, used to treat eczema and asthma. Based in Tarrytown, New York, Regeneron employs cutting-edge technologies like its VelociSuite platform, which enhances drug invention capabilities. The company plays a significant role in the biotechnology sector by delivering high-impact therapies that improve patient outcomes. With a strong emphasis on research and development, Regeneron continues to expand its impact across global markets, providing vital solutions to complex health challenges.
Never miss another REGN filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.